GeoVax Labs (GOVX) Stock Price, News & Analysis

Company Overview

GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs. This dual approach is designed to stimulate both cellular and humoral immunity, a feature that has supported advancement of the company’s HIV vaccine candidate through Phase 2 clinical trials. GeoVax is also applying this platform to develop next-generation vaccines for hemorrhagic fever viruses and novel coronaviruses, targeting populations in regions prone to outbreaks as well as frontline health workers.

Founded in 2001 and headquartered in Atlanta, Georgia, GeoVax operates in collaboration with academic institutions, government agencies and non-profit organizations. The company has received funding and technical support from the National Institutes of Health (NIH), the U.S. Department of Defense and other global health partners. These collaborations have advanced preclinical programs and facilitated clinical trial design, positioning GeoVax to rapidly respond to emerging infectious disease challenges.

Leadership at GeoVax is headed by President and Chief Executive Officer James W. Bunn, who brings more than two decades of experience in biotechnology operations and clinical development. Under his direction, the management team continues to refine the company’s vaccine platform and expand its pipeline. GeoVax’s board of directors and scientific advisory board comprise experts in virology, immunology and vaccine development, guiding strategic decisions as the company advances toward late-stage clinical studies and potential licensing partnerships.

Key Stats

• Today's Range: $0.54 to $0.56
• 50-Day Range: $0.47 to $0.78
• 52-Week Range: $0.43 to $3.88
• Volume: 548,149 shs
• Average Volume: 1.28 million shs
• Market Capitalization: $16.41 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.50
• Consensus Rating: Moderate Buy

GeoVax Labs Stock Analysis - MarketRank™

GeoVax Labs scored higher than 46% of companies evaluated by MarketBeat, and ranked 647th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

GeoVax Labs has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

GeoVax Labs has a consensus price target of $8.50, representing about 1,438.5% upside from its current price of $0.55.

Amount of Analyst Coverage

GeoVax Labs has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for GeoVax Labs are expected to grow in the coming year, from ($4.49) to ($1.12) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GeoVax Labs is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of GeoVax Labs is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

GeoVax Labs has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

12.46% of the outstanding shares of GeoVax Labs have been sold short.

Short Interest Ratio / Days to Cover

GeoVax Labs has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GeoVax Labs has recently decreased by 2.37%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GeoVax Labs does not currently pay a dividend.

Dividend Growth

GeoVax Labs does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.46% of the outstanding shares of GeoVax Labs have been sold short.

Short Interest Ratio / Days to Cover

GeoVax Labs has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GeoVax Labs has recently decreased by 2.37%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.17

News Sentiment

GeoVax Labs has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for GeoVax Labs this week, compared to 2 articles on an average week.

Search Interest

15 people have searched for GOVX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

4 people have added GeoVax Labs to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, GeoVax Labs insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.20% of the stock of GeoVax Labs is held by insiders.

Percentage Held by Institutions

Only 6.09% of the stock of GeoVax Labs is held by institutions.

GOVX Stock Analysis - Frequently Asked Questions

How have GOVX shares performed this year?

GeoVax Labs' stock was trading at $2.47 at the beginning of the year. Since then, GOVX shares have decreased by 77.6% and is now trading at $0.5525.

How were GeoVax Labs' earnings last quarter?

GeoVax Labs Inc. (NASDAQ:GOVX) issued its quarterly earnings results on Monday, July, 28th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.06. The company earned $0.85 million during the quarter, compared to analyst estimates of $0.37 million. GeoVax Labs had a negative trailing twelve-month return on equity of 408.80% and a negative net margin of 403.88%.
Read the conference call transcript.

When did GeoVax Labs' stock split?

GeoVax Labs shares reverse split on Wednesday, January 31st 2024.The 1-15 reverse split was announced on Wednesday, January 31st 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 31st 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of GeoVax Labs?

Shares of GOVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of GeoVax Labs own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GeoVax Labs investors own include Plug Power (PLUG), FuelCell Energy (FCEL), Workhorse Group (WKHS), KALA BIO (KALA), Lipocine (LPCN), Fortress Biotech (FBIO) and Ovid Therapeutics (OVID).

Company Calendar

• Last Earnings: 7/28/2025
• Today: 10/18/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GOVX
• CIK: 832489
• Web: www.geovax.com
• Phone: (678) 384-7220
• Fax: 678-384-7281
• Employees: 10
• Year Founded: 2001

Price Target and Rating

• Average Price Target for GeoVax Labs: $8.50
• High Price Target: $9.00
• Low Price Target: $8.00
• Potential Upside/Downside: +1,438.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$24.99 million
• Net Margins: -403.88%
• Pretax Margin: -403.88%
• Return on Equity: -408.80%
• Return on Assets: -279.89%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.03
• Quick Ratio: 2.03

Sales & Book Value

• Annual Sales: $3.95 million
• Price / Sales: 4.15
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.48 per share
• Price / Book: 1.15

Miscellaneous

• Outstanding Shares: 29,700,000
• Free Float: 29,349,000
• Market Cap: $16.41 million
• Optionable: Not Optionable
• Beta: 3.31